APTARGROUP, INC. (ATR): Aptar Reports Third Quarter 2026 Results
APTARGROUP, INC. (ATR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aptar Reports Third Quarter 2026 Results Crystal Lake, Illinois, October 29, 2026 -- AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today reported the following third quarter results
How this was made
The 30-second read
Why it matters
The quarter shows reported sales growth and segment outperformance, while profitability softened via lower adjusted EBITDA margins and a material Russia-related deconsolidation loss and tax effects. The company also provides a concrete Q4 adjusted EPS range, which is the primary near-term decision input for traders.
Market read
Traders can update positioning based on fresh Q3 results, the Russia deconsolidation accounting/tax impacts, and the stated Q4 adjusted EPS range.
What to watch
The Russian deconsolidation drove a large after-tax loss and a higher reported effective tax rate; investors may reprice risk and volatility rather than extrapolate segment growth alone.
Aptar reported third-quarter sales growth across all three segments, while Russian subsidiary deconsolidation reduced reported earnings and adjusted EBITDA margins declined year over year.
Reported sales increased 6% and all three segments grew, but reported diluted EPS fell to $0.51 from $1.92 following the Russia deconsolidation impact, while adjusted EPS declined to $1.52 from $1.62 and adjusted EBITDA margin fell to 21.3% from 23.2%.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net Sales, three months ended September 30GAAP | $1.02B | – | 6% |
| Core sales growth, three months ended September 30non-GAAP | 5% | – | 5% |
| Cost of Sales, three months ended September 30GAAP | 646.2M | – | – |
| Selling, Research & Development and Administrative, three months ended September 30GAAP | 160.2M | – | – |
| Depreciation and Amortization, three months ended September 30GAAP | 75.54M | – | – |
| Restructuring Initiatives, three months ended September 30GAAP | 2.21M | – | – |
| Operating Income, three months ended September 30GAAP | 135.0M | – | – |
| Loss on Russia Deconsolidation, three months ended September 30GAAP | −58.02M | – | – |
| Income before Income Taxes, three months ended September 30GAAP | 60.33M | – | – |
| Provision for Income Taxes, three months ended September 30GAAP | 27.51M | – | – |
| Reported effective tax rate, three months ended September 30GAAP | 45.6% | – | – |
| Adjusted effective tax rate, three months ended September 30non-GAAP | 23.4% | – | – |
| Net Income, three months ended September 30GAAP | $32.82M | – | – |
| Net Income Attributable to AptarGroup, Inc., three months ended September 30GAAP | $32.60M | – | – |
| Diluted earnings per share, three months ended September 30GAAP | $ 0.51 | – | – |
| Adjusted net income attributable to AptarGroup, Inc. per diluted share, three months ended September 30non-GAAP | $ 1.52 | – | – |
| Adjusted EBITDA, three months ended September 30non-GAAP | $217.2M | – | – |
| Adjusted EBITDA margin, three months ended September 30non-GAAP | 21.3 % | – | – |
| Net Sales, nine months ended September 30GAAP | $3.03B | – | 8% |
| Core sales growth, nine months ended September 30non-GAAP | 2% | – | 2% |
| Operating Income, nine months ended September 30GAAP | 369.2M | – | – |
| Net Income, nine months ended September 30GAAP | $193.6M | – | – |
| Net Income Attributable to AptarGroup, Inc. per diluted share, nine months ended September 30GAAP | $ 3.00 | – | decrease of 37% |
| Adjusted Net Income Attributable to AptarGroup, Inc. per diluted share, nine months ended September 30non-GAAP | $ 4.13 | – | decreased 10% |
| Adjusted EBITDA, nine months ended September 30non-GAAP | $618.7M | – | – |
| Adjusted EBITDA margin, nine months ended September 30non-GAAP | 20.4 % | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Pharma, three months ended September 30Growth in central nervous system and pulmonary therapies, nasal decongestants, eye care, dermal drug delivery solutions, and demand related to biologics, vaccines and GLP-1 therapies was partially offset by the anticipated reduction in emergency medicine sales. | $454.0M | – | Reported Sales Growth 2%; Core Sales Growth 1% |
| Beauty, three months ended September 30Increased demand for prestige fragrance dispensing, color cosmetics and hair care applications, along with pass throughs of higher input costs. | $357.4M | – | Reported Sales Growth 9%; Core Sales Growth 8% |
| Closures, three months ended September 30Beverage and food sales grew significantly, led by bottled water and concentrates, beverage dispensing closure innovation and condiment sales; pass throughs of higher input costs contributed positively to core sales growth. | $207.8M | – | Reported Sales Growth 11%; Core Sales Growth 11% |
| Pharma, nine months ended September 30 | $1.35B | – | Total Reported Sales Growth 4%; Core Sales Growth 0% |
| Beauty, nine months ended September 30 | $1.09B | – | Total Reported Sales Growth 12%; Core Sales Growth 4% |
| Closures, nine months ended September 30 | $589.3M | – | Total Reported Sales Growth 7%; Core Sales Growth 5% |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Fourth quarter of 2026 outlook
- Tax rate17.5% to 19.5%
- NoteAdjusted earnings per share: $1.39 to $1.47
- NoteEarnings per share guidance range assumes a 1.12 Euro to USD exchange rate.
Capital returns
- Returned $61 million in the quarter and $272 million year-to-date to shareholders through share repurchases and dividends.
- Repurchased approximately 234 thousand shares for $30 million during the third quarter.
- Dividends paid were (92,054) (In Thousands) for the nine months ended September 30, 2026.
- Purchase of treasury stock was (179,973) (In Thousands) for the nine months ended September 30, 2026.
- Board of Directors approved a quarterly cash dividend of $0.50 per share, payable December 3, 2026, to stockholders of record as of November 12, 2026.
- The Board approved an increase in the quarterly cash dividend from $0.48 to $0.50.
What drove it
- Aptar reported broad-based revenue growth across all three segments.
- Pharma adjusted EBITDA margin was 36.4 %, supported by royalties and productivity improvements.
- Beauty growth reflected demand in prestige fragrance dispensing, color cosmetics and hair care applications.
- Closures growth reflected beverage and food demand and momentum in beverage dispensing closure innovation.
- Higher input-cost pass throughs contributed positively to sales growth in Beauty and Closures.
Concerns
- Aptar recorded a $58.0 million loss on deconsolidation of its Russian subsidiary following a governmental decree placing the subsidiary under external administration and the resulting loss of control.
- The combined Russia deconsolidation impact was $61.2 million before tax and $60.4 million after tax, or $0.94 per diluted share.
- The third-quarter reported effective tax rate was 45.6%, reflecting the non-deductible tax impact of the Russian subsidiary deconsolidation.
- Pharma faced an anticipated reduction in emergency medicine sales and short-term unfavorable product mix related to destocking.
- Beauty adjusted EBITDA margin was 11.4 %, including unfavorable mix and ongoing challenges in North American operations.
- Closures adjusted EBITDA margin declined 60 basis points to 15.5% because of the dilutive impact of higher input-cost pass throughs.
What to watch
- Fourth-quarter adjusted earnings per share guidance of $1.39 to $1.47 and the assumed effective tax rate range of 17.5% to 19.5%.
- Whether Pharma growth in consumer healthcare and injectables proceeds without the emergency medicine destocking headwind.
- Execution on improving Beauty's long-term North American trajectory.
- Continuing demand for Closures beverage technologies and the impact of input-cost pass throughs on profitability.
- Recovery of value from, and the continuing consequences of, Aptar's Russian operations.
Balance sheet and cash flow
- Cash and Equivalents were $ 204,176 (In Thousands) at September 30, 2026, compared with $ 402,424 (In Thousands) at December 31, 2025.
- Short-Term Obligations were $ 350,681 (In Thousands) at September 30, 2026, compared with $ 343,531 (In Thousands) at December 31, 2025.
- Long-Term Obligations were $ 1,024,735 (In Thousands) at September 30, 2026, compared with $ 1,139,433 (In Thousands) at December 31, 2025.
- Net Cash Provided by Operations was $ 167,598 (In Thousands) for the three months ended September 30, 2026, compared with $ 177,606 (In Thousands) in 2025.
- Free Cash Flow was $ 98,592 (In Thousands) for the three months ended September 30, 2026, compared with $ 114,293 (In Thousands) in 2025.
- Net Cash Provided by Operations was $ 389,778 (In Thousands) for the nine months ended September 30, 2026, compared with $ 386,306 (In Thousands) in 2025.
- Capital Expenditures were (191,965) (In Thousands) for the nine months ended September 30, 2026, compared with (183,600) (In Thousands) in 2025.
- Free Cash Flow was $ 197,813 (In Thousands) for the nine months ended September 30, 2026, compared with $ 206,014 (In Thousands) in 2025.
- Cash balance of deconsolidated subsidiary was (29,977) (In Thousands) for the nine months ended September 30, 2026.
Analysis
Aptar delivered $ 1,019,119 (In Thousands) of third-quarter net sales, up 6%, and core sales growth of 5%. Growth was broad based, with reported sales growth of 2% in Pharma, 9% in Beauty and 11% in Closures. The nine-month sales result was $ 3,028,495 (In Thousands), up 8%, although nine-month core sales growth was 2% after currency effects and acquisitions or deconsolidation effects.
Management, verbatim
We delivered broad-based revenue growth across all three segments. Pharma delivered impressive growth in central nervous system therapies, pulmonary, injectables and consumer healthcare, while maintaining profitability at the high end of our long-term target range.
Gael Touya, Aptar President and CEO
We expect Aptar to finish the year strong, supported by continued Pharma growth, particularly in consumer healthcare and injectables and without the headwind from emergency medicine destocking.
Gael Touya, Aptar President and CEO
Not in the filing
stated, not guessed- GAAP gross margin for the three months ended September 30, 2026 and 2025
- GAAP gross margin for the nine months ended September 30, 2026 and 2025
- Quarterly total debt
- Fourth-quarter 2026 revenue guidance
- Fourth-quarter 2026 gross-margin guidance
- Fourth-quarter 2026 operating-expense guidance
- Prior-quarter comparisons for reported financial metrics
- Prior outlook for comparison with third-quarter actual results
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is AptarGroup’s SEC 8-K furnishing Q3 2026 results and Q4 2026 outlook, including impacts from deconsolidating its Russian subsidiary.
Ticker impact
Aptar reported Q3 2026 sales up 6% to $1.02B, with adjusted EPS $1.52 at the high end of its Q4 guidance range.
Likely modest upside bias as investors focus on Pharma and Closures growth plus Q4 EPS guidance, tempered by lower adjusted EBITDA margins and the Russian deconsolidation tax impact.
The filing provides fresh quarter results, a specific Q4 adjusted EPS range ($1.39 to $1.47), and detailed impacts from deconsolidating the Russian subsidiary, which should drive near-term repricing.
Market effects
Provides a datapoint on demand trends in drug delivery and dispensing components, especially Pharma growth and Closures beverage momentum.
Russia deconsolidation highlights ongoing geopolitical and operational risk for multinational med-tech suppliers.
Signals continued resilience in parts of healthcare dispensing supply chains, with tax and margin volatility tied to geopolitical exposure.
Counterpoint
Adjusted EPS is at the high end of guidance, but adjusted EBITDA margins declined across segments, suggesting earnings quality may be pressured by mix and North American operational challenges.
Key entities
- companyAptarGroup, Inc.
Global drug delivery, dosing, and protection technologies provider reporting Q3 2026 results and Q4 2026 adjusted EPS guidance.
- eventRussian subsidiary deconsolidation
Government decree led to external administration, loss of control, and a $58.0M loss on deconsolidation with after-tax impact of $60.4M.
- executiveGael Touya
President and CEO quoted on segment performance and capital allocation priorities.
